article thumbnail

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Pharmaceutical Technology

It is expected to accelerate the development of CFT8919 in important international markets. In vivo and in vitro pre-clinical studies demonstrated that CFT8919 provides wider coverage of on-target resistant mutations and intracranial activity, indicating its potential to be effective against brain metastases.

In-Vivo 130
article thumbnail

ZNA-1041 by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval

Pharmaceutical Technology

ZNA-1041 is under clinical development by F. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Hoffmann-La Roche and currently in Phase I for Solid Tumor. Buy the report here.

In-Vitro 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NRG raises Series A funds for Parkinson’s and ALS therapy development

Pharmaceutical Technology

The pre-clinical pipeline of NRG comprises small molecule assets that use a new mechanism of action to hinder the mitochondrial permeability transition pore (mPTP). . According to data from vitro studies, the investigational new drugs of the company have been shown to protect mitochondria and enhance human cell viability.

article thumbnail

Pralsetinib by F. Hoffmann-La Roche for Pancreatic Cancer: Likelihood of Approval

Pharmaceutical Technology

Pralsetinib is under clinical development by F. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Hoffmann-La Roche and currently in Phase II for Pancreatic Cancer. Buy the report here.

In-Vitro 100
article thumbnail

Pfizer/BioNTech Begin Studies for Third Booster Dose and Development of COVID-19 Vaccine Variants

XTalks

Pfizer/BioNTech are executing the three-dose study to also determine the effectiveness of a third dose against evolving variants as part of their clinical development strategy. Sera from individuals will also be taken to evaluate neutralization of different SARS-CoV-2 strains in in vitro studies.

Vaccine 111
article thumbnail

Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?

Pharmaceutical Technology

According to Globaldata, it is involved in 5 clinical trials, which are ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. It also develops RNAi candidates for the treatment of retina diseases. Buy the model here. over FY2021.

Hormones 100
article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

There were developments in the past 12 months, true – Biogen/Eisai’s lecanemab (now branded Leqembi) showed clear success in the Clarity AD trial and received approval by FDA on 6th January 2023. The hard problem: innovation for high prevalence, chronic diseases of ageing.